Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sarepta Therapeutics
(NQ:
SRPT
)
122.03
-0.30 (-0.24%)
Streaming Delayed Price
Updated: 12:23 PM EDT, Oct 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Benzinga Pro's Top 5 Stocks To Watch For Monday, May 15, 2023: TSLA, SRPT, TJX, MNDY, LTRY
May 15, 2023
Tesla (TSLA) - The company will host its annual shareholder meeting on Tuesday. The event will be broadcast on YouTube and begins at 4 p.m. EDT. A reminder that annual shareholder meetings are
Via
Benzinga
Why Sarepta Therapeutics Stock Is Soaring Today
May 15, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading higher Monday after the company announced the FDA voted in favor of its gene therapy to treat Duchenne muscular dystrophy late...
Via
Benzinga
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
May 15, 2023
On Friday, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene...
Via
Benzinga
2 Supercharged Growth Stocks to Buy Right Now
May 14, 2023
These two biopharma stocks might be poised for a major breakout.
Via
The Motley Fool
Sarepta Therapeutics Announces Positive Vote from U.S. FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
May 12, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Why Sarepta Therapeutics Stock Faded This Week
May 11, 2023
The biotech's shares have turned volatile ahead of an important regulatory event.
Via
The Motley Fool
Sarepta: The AdCom Documents Enter The Discussion
May 10, 2023
The AdCom documents are going to stimulate a robust discussion about the upcoming vote.
Via
Talk Markets
Expert Ratings for Sarepta Therapeutics
May 03, 2023
Via
Benzinga
Sarepta Halted As FDA Mulls Its Highly Anticipated Gene Therapy
May 12, 2023
The gene therapy would treat Duchenne muscular dystrophy, a muscle-wasting disease.
Via
Investor's Business Daily
FDA Staff Raises Issues For Sarepta's Duchenne Gene Therapy Data, Analyst Says Issues Known, Expects Positive Vote
May 10, 2023
The FDA's Cellular, Tissue and Gene Therapies Advisory Committee is meeting this Friday to discuss Sarepta Therapeutics Inc's (NASDAQ: SRPT) to review SRP-9001 (delandistrogene moxeparvovec),...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 10, 2023
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
May 09, 2023
Via
Benzinga
Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript
May 03, 2023
SRPT earnings call for the period ending March 31, 2023.
Via
The Motley Fool
Sarepta Therapeutics Earnings Preview
May 01, 2023
Via
Benzinga
Sarepta: More Drama Or Just More Noise?
April 14, 2023
Sarepta has a history at the FDA and recent reports indicate additional issues. What are the implications for accelerated approval and the long term prospects of Sarepta?
Via
Talk Markets
The Latest Analyst Ratings for Sarepta Therapeutics
April 14, 2023
Via
Benzinga
Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review
May 05, 2023
The major indexes retreated for most of the week on banking fears,
Via
Investor's Business Daily
Sarepta Therapeutics Announces First Quarter 2023 Financial Results and Recent Corporate Developments
May 02, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 28, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
Sarepta Therapeutics to Announce First Quarter 2023 Financial Results
April 25, 2023
From
Sarepta Therapeutics, Inc.
Via
Business Wire
This Biotech's Stock Has Been Under Pressure, Could Upcoming Clinical Trials Of Its Nanotechnology-Based COVID Drug Candidate Be The Start Of An Upward March?
April 19, 2023
A company that seems to have seen poor market sentiment lately is NanoViricides Inc. (NYSEAMERICAN: NNVC), a pharmaceutical company specializing in the development of nanomedicine drugs for treating...
Via
Benzinga
Bragar Eagel & Squire, P.C. Is Investigating Fox, Charles River, Provident, and Sarepta and Encourages Investors to Contact the Firm
April 17, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
Analysts Says Stat News Article Adds Uncertainty To Sarepta's SRP-9001, But Offers Buying Opportunity Around The Weakness
April 13, 2023
Via
Benzinga
FDA Staff Had Inclination Towards Rejecting Sarepta Duchenne Gene Therapy
April 13, 2023
Reviewers at the FDA were leaning toward rejecting Sarepta Therapeutics Inc's (NASDAQ: SRPT) closely watched gene therapy for Duchenne muscular dystrophy.
Via
Benzinga
Sarepta Tumbles As Report Of Internal FDA Strife Scorches Its Gene Therapy
April 13, 2023
According to a report, some staffers wanted to reject the highly watched drug.
Via
Investor's Business Daily
Why Is Merck (MRK) Stock Up Today?
April 13, 2023
Merck (MRK) stock is on the move Thursday after the pharmaceutical company got an update from the FDA concerning Keytruda.
Via
InvestorPlace
Why Is BigBear.ai (BBAI) Stock Down 5% Today?
April 13, 2023
BigBear.ai (BBAI) stock is taking a beating on Thursday after the AI company announced the details of a public stock offering.
Via
InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Down 12% Today?
April 13, 2023
Sarepta Therapeutics (SRPT) stock is taking a beating on Thursday following reports that the FDA was considering rejecting one of its drugs.
Via
InvestorPlace
Why Sarepta Therapeutics Stock Is Tumbling Today
April 13, 2023
Sarepta Therapeutics Inc (NASDAQ: SRPT) shares are trading lower Thursday on the heels of a report suggesting some U.S. Food and Drug Administration staff had opposition towards Sarepta gene therapy...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 13, 2023
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.